Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| DOH-97-DC-1502 | Other Grant/Funding Number | Taiwan CDC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
LTBI Treatment is effective in prison
LTBI treatment will be conducted in a prison with either isoniazid or rifampin
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 2 | No Intervention | For patients who diagnosed with LTBI, they choose to receive LTBI treatment depends on their willingness; if they choose not, then they are in no intervention arm. | |
| 1 | Experimental | Provided INH 6m or RMP 4 m; whether enter treatment arm is determined by patient's willingness |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| isoniazid , randomized, open label | Drug | isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin) |
|
| Measure | Description | Time Frame |
|---|---|---|
| COMPLETE RATE OF LTBI TREATMENT | 1.5 year |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy | 3 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Li-Min Huang, MD, PHD | National University Hospital, Singapore | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Taipei Prison | Taoyuan | Taiwan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22410137 | Derived | Chan PC, Yang CH, Chang LY, Wang KF, Lu BY, Lu CY, Shao PL, Hsueh PR, Fang CT, Huang LM. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis. 2012 May;16(5):633-8. doi: 10.5588/ijtld.11.0504. Epub 2012 Mar 8. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| ID | Term |
|---|---|
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D007538 | Isoniazid |
| D011897 | Random Allocation |
| D012293 | Rifampin |
| ID | Term |
|---|---|
| D006834 | Hydrazines |
| D009930 | Organic Chemicals |
| D007539 | Isonicotinic Acids |
| D000147 | Acids, Heterocyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| rifampin, randomized, open label | Drug | rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid) |
|
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D006571 |
| Heterocyclic Compounds |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
| D008722 | Methods |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |
| D012294 | Rifamycins |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D047029 | Lactams, Macrocyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |